12 protocols meet the specified criteria

OCR17388

A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors

OCR17458

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors (SGNTV-001)

OCR31722

Clinically-Efficient Strategies to Address Tobacco Smoke Exposure in Pediatric Practice

OCR33062

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

OCR37342

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

OCR38884

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

OCR40664

Precision Cancer Survivorship Cohort

OCR41744

Increasing patient portal adoption among Black cancer patients: Designing messaging and identifying proper communication channels

OCR41889

Cancer Knowledge, Quality of Life, Health Behaviors, and Views About Health Care and Medical Research among Adult Cancer Survivors and Adults At-Risk for Cancer: A Study by the UF Health Cancer Center s Community-Partnered Cancer Disparities Research Collaborative

OCR41944

Population Health Assessment in the UFHCC Catchment Area Random Digit Dialing Survey: Cancer Screening Knowledge and Health Habits in the UFHCC Catchment Area

OCR42090

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

OCR42568

Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas